A 48-year-old woman hospitalized for 10 days with pneumonia develops a secondary bloodstream infection. Blood culture grows a gram-negative rod resistant to carbapenems (meropenem MIC >4 μg/mL). Routine disk diffusion shows resistance to ceftriaxone, cefepime, and carbapenems. Which investigation is most appropriate to identify the mechanism of carbapenem resistance?

Explanation

## Diagnosis of Carbapenem Resistance **Key Point:** Carbapenem resistance in gram-negative bacteria is a hallmark of carbapenemase production. The clinical context (nosocomial infection, high carbapenem MIC) and resistance pattern (resistance to carbapenems) mandate identification of the carbapenemase mechanism. ### Investigation of Choice: Modified Hodge Test The **Modified Hodge test (MHT)** is the gold-standard phenotypic screening test for carbapenemase production: #### Principle & Technique 1. **Substrate:** Meropenem disk placed at the center of Mueller-Hinton agar plate. 2. **Inoculum:** Carbapenem-susceptible indicator strain (e.g., *Escherichia coli* ATCC 25922) streaked from the disk outward. 3. **Positive Result:** Enhanced growth ("cloverleaf" or "halo" pattern) of the indicator strain around the meropenem disk indicates carbapenemase production. 4. **Interpretation:** Carbapenemase inactivates meropenem → indicator strain grows in the zone of inhibition. #### Sensitivity & Specificity - **Sensitivity:** ~90–95% for detecting carbapenemase (KPC, NDM, OXA, VIM, IMP). - **Specificity:** ~95% (rare false positives with porin loss + ESBL). **High-Yield:** MHT is the most practical, cost-effective, rapid (24 hours) screening test for carbapenemase in clinical microbiology labs across India and resource-limited settings. ### Comparison of Resistance Detection Methods | Test | Detects | Mechanism | Limitation | |------|---------|-----------|------------| | **Modified Hodge** | Carbapenemase | Phenotypic (enzyme activity) | Cannot identify specific carbapenemase type | | **DDST + Clavulanic Acid** | ESBL (not carbapenemase) | β-lactamase inhibition | Irrelevant for carbapenem-resistant isolates | | **Cefoxitin Disk (AmpC)** | AmpC β-lactamase | Cephamycin resistance | Does not detect carbapenemase; AmpC ≠ carbapenemase | | **Fluoroquinolone MIC** | Fluoroquinolone susceptibility | Unrelated to carbapenem resistance | Does not identify mechanism of carbapenem resistance | **Clinical Pearl:** Carbapenem-resistant gram-negative bacteria are a critical nosocomial threat. MHT is the first-line phenotypic test; if positive, molecular testing (PCR for *bla*~KPC~, *bla*~NDM~, *bla*~OXA~) or MALDI-TOF mass spectrometry can identify the specific carbapenemase type for epidemiological tracking and infection control. **Mnemonic:** **MHT = Modified Hodge Test** — **"Hodge"** detects carbapenemase by observing the **"halo"** of indicator organism growth. **Warning:** Do not confuse ESBL (inhibited by clavulanic acid, susceptible to carbapenems) with carbapenemase (resistant to carbapenems, detected by MHT). This patient has carbapenem resistance → MHT, not DDST. [cite:Koneman's Textbook of Diagnostic Microbiology Ch 9; CLSI M100 Guidelines]